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A report on the 42nd Annual Meeting of the American Society
for Cell Biology, San Francisco, 14-18 December 2002.
Visions for the post-genomic world 
The American Society for Cell Biology takes public policy
issues very seriously. At the Society’s 42nd annual meeting,
one key concern was research funding. Elias Zerhouni, the
new Director of the US National Institutes of Health (NIH;
Bethesda, USA) addressed issues of funding, the direction of
science and the way in which it must be practised in the
future. He began by explaining the problem he has to explain
to the US Congress - why is it that a 100% increase in NIH
funding will only result in a 40% increase in the number of
grants? The difference is mainly due to the increasing costs
(the average grant has gone from $255,000 in 1998 to
$370,000 in 2003) and the multi-year commitments;
despite this problem, Zerhouni is proud that the funding
level remains at about 30% of submitted grant proposals,
and that about one third of newly funded grants are for new
investigators. He also recognizes the threat to the future of
science if we don’t adequately nurture young scientists. “You
don’t become a thoroughbred,” he said, “by longevity.”
Only about 4% of NIH-funded researchers are 35 or under,
creating a difficult situation for many young workers. Only
half the NIH grantees have their grants renewed after four
years, and only about 4% of grantees have been funded for
over twenty years.
Turning to the current and future state of biomedical
research, Zerhouni defined the unifying concepts as ‘omics’
(genome-scale studies of all kinds), signaling, apoptosis,
trafficking within the cell, and cell-cycle control. He identified
the “mathematicization” of biology and has observed an
increasing emphasis on epigenetics - differential gene
expression and its controls. He maintained that we cannot
address the complexity of these problems with today’s
methods and with today’s organization of research teams.
We are in a race against time, with pressure for more rapid
translation of research into clinical reality, and more atten-
tion to research on ‘molecular prevention’ and behavioral
modification. His four priorities for the NIH are revolution-
ary methods, new pathways to discovery, multidisciplinary
research teams, and re-engineering of clinical research. 
Nuclear motors
Primal de Lanerolle (University of Illinois, Chicago, USA)
described an interesting role for actins and myosins in the
regulation of transcription. It has been known for more
than 20 years that actin is present in the nucleus, and the
recent demonstration by De Lanerolle and colleagues of the
presence of an unconventional myosin (myosin I) in the
nucleus has suggested that actin and myosin I function
together as a molecular motor in the nucleus; but the role of
these molecules, if any, in transcription has not been clear.
To address this question, De Lanerolle and colleagues injected
antibodies against actin into the nucleus of mammalian cells
and found that an antibody to non-muscle -actin inhibited
transcription by RNA polymerase II. In a variety of experi-
ments using western blots, de Lanerolle showed that some
-actin co-purified with RNA polymerase II; and the antibody
to  -actin inhibited transcription even in reconstituted
transcription complexes. Evidently one of the functions of
actin is in the formation of pre-initiation complexes: it was
found in these complexes and was shown to co-immuno-
precipitate with the TATA-binding protein (TBP). De
Lanerolle also speculated that actin and myosin I are
involved in transcriptional elongation. Although unconven-
tional myosins do not form filaments, myosin I has a positively
charged domain that binds to negatively charged lipids and
possibly to DNA. De Lanerolle speculated that the tail of
myosin binds to DNA filaments and that the myosin head
then interacts with actin in the transcription complex,
performing an astoundingly similar role to that of sarcomeric
actin and myosin in muscle contraction.RNA regulates the genome 
Time and again, model organisms have provided key
insights into cellular processes that have later been recog-
nized in higher eukaryotes such as humans. When a maize
geneticist mentioned ‘paramutation’ at a human genetics
meeting less than a decade ago, there was some skepticism;
now, phenomena known as post-transcriptional gene silenc-
ing in plants and quelling in the fungus Neurospora are
appearing under the name RNA interference (RNAi) in
mainstream yeast and mammalian molecular biology. At this
meeting, Marjori Matzke (Austrian Academy of Sciences,
Salzburg, Austria) explained how RNA-directed DNA methy-
lation (RdDM) regulates gene expression in Arabidopsis.
Whereas RNAi involves the cleavage of a target mRNA medi-
ated by double-stranded RNA, RdDM acts at the transcrip-
tional level. RNA-DNA base-pairing near the promoter acts
as a signal for methylation of cytosines in the DNA region,
silencing gene expression. The process methylates virtually
all cytosines in the region, not just the CpG dinucleotides
that are characteristically affected by mammalian DNA
methyltransferases. The mechanism is poorly understood,
but members of Matzke’s laboratory are screening mutants
and have begun to catalog the proteins involved in RdDM.
Experiments have shown that two genes, encoding the
methylase MET1 and the histone deacetylase HDA6, are
required for maintenance of RdDM methylation. The de
novo methylase involved in RdDM has not yet been identi-
fied, but MET1 is a strong candidate. RdDM hasn’t yet made
its debut in mammalian genetics, but Matzke pointed out
that non-CpG methylation is important in very early mam-
malian development.
The dosage-compensation complex 
In the nematode Caenorhabditis elegans, hermaphrodites
have two X chromosomes while males have only one, and
expression of X-linked genes is made equivalent in the two
sexes by a two-fold downregulation of the two X chromo-
somes in hermaphrodites. In mammals, on the other hand,
one of the two X chromosomes is inactivated in each cell in
females; and in Drosophila melanogaster, the single X
chromosome in males is upregulated two-fold to attain
dosage compensation; non-coding RNAs are known to be
involved in both mammals and insects. Now that RNA
interference is all the rage, it is surprising that no non-
coding RNA molecule has yet been associated with the
dosage-compensation process in C. elegans. We might be in
a better position to find such an RNA, however, when we
understand better the loci on the X chromosome that might
be essential for dosage compensation. Gyorgyi Csankovszki,
from Barbara Meyer’s laboratory (University of California,
Berkeley, USA), is elucidating some of the cis-acting ele-
ments along the C. elegans X chromosome that might be
involved. Meyer’s laboratory has described at least seven
proteins that are essential for formation of the dosage com-
pensation complex on the hermaphrodite X chromosomes;
some of these are also involved in other chromosomal
processes, including meiosis and mitosis. 
In mammals, X inactivation nucleates at a single site, called
the X-inactivation center, that harbors the locus for the non-
coding RNA XIST (for X-inactive-specific transcript).
Csankovszki explained that a similar point of origin for
dosage compensation on the C. elegans X chromosome has
not yet been described. On the Drosophila X chromosome,
there appear to be many such points of origin, at least two of
which are loci for the non-coding RNA molecules Rox1 and
Rox2, which are required for dosage compensation. Until
Csankovszki’s work, we did not know whether there were one,
a few or many similar points of nucleation for dosage com-
pensation in C. elegans. Using animals with small duplica-
tions of the X chromosome, she showed that some regions
were able to recruit the dosage-compensation complex,
whether they were free-floating or attached to autosomes,
while others could not. (As C. elegans chromosomes are holo-
centric, all fragments have centromeric activity and so are not
lost as they would be in other organisms.) Additional work
will be required to determine whether or not gene expression
is appropriately regulated in the duplicated regions. This
work strongly suggests that there are, indeed, multiple sites
for the nucleation of dosage compensation in C. elegans, but
that they are spaced some distance apart. With a refined
experimental system, Csankovszki and her colleagues will be
able to identify specific DNA sequences that recruit the
dosage-compensation complex and that may serve as initia-
tion points for dosage compensation. One or more of the cis-
acting regions involved in C. elegans dosage compensation
might, in fact, be transcribed into a hypothetical non-coding
RNA that could be analogous to XIST. We may be on a fast
track to a very exciting convergence of mammalian, insect
and worm X-chromosome regulatory mechanisms. 
RNA-mediated regulation of gene expression may be the hot
topic of the day, but it is only the latest part of a growing
body of evidence that while the genome may give us the raw
ingredients of life, it is surely the ‘epigenome’ that gives us
the spice. At no time has it been more apparent that the cell
biologists will be the chefs. Abstracts of the meeting are
available at the American Society for Cell Biology website
[http://www.ascb.org] or as a supplement to Molecular
Biology of the Cell, volume 13.
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